Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
Rhea-AI Summary
Protagonist Therapeutics (PTGX) will present four abstracts on rusfertide in polycythemia vera at the 2026 European Hematology Association Congress in Stockholm, June 11-14, 2026.
Data span the Phase 3 VERIFY trial and long-term Phase 2 REVIVE and THRIVE extension studies, covering efficacy, safety, cytoreductive therapy use, thromboembolic and progression events, and patient-reported outcomes.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PTGX
On the day this news was published, PTGX declined 4.66%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PTGX slipped 0.85% while close biotech peers showed mixed moves (e.g., MIRM +1.78%, ZLAB -1.99%), and no peers appeared in the momentum scanner, pointing to a stock-specific reaction.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Rusfertide NDA filing | Positive | -3.4% | NDA submission for rusfertide in PV with VERIFY Phase 3 data. |
| Sep 17 | Psoriasis, PN-881 data | Positive | +1.1% | Phase 3 icotrokinra psoriasis data and potent PN-881 preclinical results. |
| Jun 01 | VERIFY Phase 3 results | Positive | +5.7% | VERIFY Phase 3 rusfertide data showing strong efficacy and safety in PV. |
| May 09 | Icotrokinra Phase 3 data | Positive | -2.2% | Phase 3 icotrokinra data in difficult psoriasis areas and PN-881 preclinical data. |
| Apr 23 | ASCO plenary selection | Positive | +0.7% | Announcement of ASCO plenary for VERIFY Phase 3 rusfertide PV study. |
Clinical data news has generally been positive but produced mixed reactions, with both rallies and sell-the-news pullbacks following strong rusfertide and icotrokinra readouts.
Over the past year, Protagonist has repeatedly highlighted clinical progress across rusfertide and icotrokinra. Key milestones include VERIFY Phase 3 rusfertide data selected for ASCO plenary sessions and later NDA submission on Jan 5, 2026, plus multiple strong Phase 3 psoriasis readouts and preclinical advances for PN-881. Price reactions to these clinical updates ranged from declines after positive NDA or psoriasis data to a 5.65% gain on VERIFY Phase 3 efficacy results, showing that strong data have not always translated into consistent upside moves.
Historical Comparison
Clinical-trial headlines for PTGX have averaged a 0.36% move. Today’s modest -0.85% reaction to additional rusfertide VERIFY/long-term data fits within this historically muted range.
The rusfertide program has progressed from ASCO plenary VERIFY Phase 3 presentations to an NDA filing for PV and now expanded Phase 3 subgroup and long-term extension data, underscoring a maturing late-stage asset.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration filed on Aug 6, 2025, expiring on Aug 6, 2028, with 0 recorded takedowns to date. This provides flexibility to raise capital in the future, though no usage has been disclosed in the provided data.
Market Pulse Summary
This announcement highlights four EHA2026 presentations expanding on rusfertide’s Phase 3 VERIFY and long-term Phase 2 data in polycythemia vera, including subgroup efficacy, safety, thromboembolic outcomes and patient-reported symptoms. Historically, PTGX clinical updates have produced mixed stock reactions, suggesting that even strong datasets do not guarantee outsized moves. Investors may watch how these data integrate with the existing VERIFY and NDA package and monitor future regulatory and commercialization milestones for rusfertide.
Key Terms
polycythemia vera medical
phase 3 medical
phase 2 medical
open-label extension medical
cytoreductive therapy medical
thromboembolic medical
patient-reported medical
AI-generated analysis. Not financial advice.
NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden. The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies.
The accepted abstracts provide additional perspective on the rusfertide clinical program in phlebotomy-dependent PV, including efficacy and safety outcomes across low-risk and high-risk patient subgroups, the effect of rusfertide on cytoreductive therapy use, long-term thromboembolic and disease progression events, and patient-reported symptom and fatigue measures.
EHA2026 Presentations:
Benefit of Rusfertide Maintained in Patients with Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis from the Randomized Controlled Phase 3 VERIFY Study
Presenting Author: Valentin Garcia Gutierrez
Session Date & Time: Poster Session 1, Friday, June 12, 18:45-19:45 CEST
Poster Number: PF892
Effect of Rusfertide on Cytoreductive Therapy Use in Patients with Phlebotomy Dependent Polycythemia Vera: Post Hoc Analysis from the Randomized Controlled Phase 3 VERIFY Study
Presenting Author: Francesca Palandri
Session Date & Time: Poster Session 1, Friday, June 12, 18:45-19:45 CEST
Poster Number: PF891
Thromboembolic and Progression Events in Phlebotomy-Dependent Patients with Polycythemia Vera: Long-Term Results from the Phase 2 REVIVE and THRIVE Open-Label Extension Rusfertide Studies
Presenting Author: Naveen Pemmaraju
Session Date & Time: Poster Session 1, Friday, June 12, 18:45-19:45 CEST
Poster Number: PF890
Impact of Rusfertide on Polycythemia Vera-Related Symptoms and Patient-Reported Outcome-Related Items in the Randomized, Double-Blind Phase 3 VERIFY Study
Presenting Author: Alessandro Lucchesi
Session Date & Time: Poster Session 1, Friday, June 12, 18:45-19:45 CEST
Poster Number: PF898
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. The Company's proprietary peptide technology platform enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra) is approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor (IL-23R) licensed to Janssen Biotech, Inc., a Johnson & Johnson company. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. An NDA for rusfertide, a first-in-class hepcidin mimetic peptide that is being co-developed with Takeda Pharmaceuticals pursuant to a worldwide license and collaboration agreement entered in 2024, is under priority review with the FDA. Protagonist holds an option to co-commercialize rusfertide in the U.S. through a 50/50 profit and loss share structure or can opt-out of this structure. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire